Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Young

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.
Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Pageof 9